Laboratorios Liomont   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Mexico City Mexico (1938)
Status: No NME R&D (1938)

Organization Overview

First Clinical Trial
2018
NCT03460743
First Marketed Drug
2020
montelukast (singulair)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Laboratorios Liomont | LABORATORIOS LIOMONT

Active Ingredients

Marketed Drugs (1)

montelukast (singulair) (2020)

Drugs in Phase 4 Trials (1)

nitazoxanide (Alinia) (1 trial)

Drugs in Phase 3 Trials (1)

inactivated influenza vaccine (1 trial)

Drugs in Phase 2 Trials (3)

etoricoxib (Gencox) (1 trial)

naproxen (naprosyn) (1 trial)

tramadol (Ultram) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 4)

Influenza, Human (Phase 3)

Severe Acute Respiratory Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5